We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
+67.6%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$313M
AUM Growth
+$218M
Cap. Flow
+$190M
Cap. Flow %
60.8%
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$190M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 92.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$211M 67.34%
+4,606,242
New +$190M
BOLD
2
DELISTED
Audentes Therapeutics, Inc
BOLD
$36.2M 11.58%
1,204,615
– –
AKAO
3
DELISTED
Achaogen Inc
AKAO
$16.6M 5.31%
1,281,152
– –
OCUL icon
4
Ocular Therapeutix
OCUL
$1.85B
$14.4M 4.61%
2,215,384
– –
CBAY
5
DELISTED
Cymabay Therapeutics
CBAY
$13.6M 4.36%
1,048,601
– –
VANI icon
6
Vivani Medical
VANI
$113M
$8.63M 2.76%
187,207
– –
IMDZ
7
DELISTED
Immune Design Corp.
IMDZ
$7.29M 2.33%
2,208,210
– –
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$5.38M 1.72%
101,855
– –

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q1 2018 Portfolio in Review

As of Q1 2018, Versant Venture Management held 8 positions worth $313M, up 229% from $95M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management deployed $190M of net new capital in Q1 2018, opening 1 new position. Its largest new stake was CRISPR Therapeutics: 4,606,242 shares worth $211M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 76% a quarter earlier.

  • Versant Venture Management's largest Q1 2018 buy was CRISPR Therapeutics: 4,606,242 shares worth $211M.
  • Versant Venture Management's ten largest holdings make up 100% of its $313M portfolio in Q1 2018.
  • Versant Venture Management opened 1 new position and closed 0 in Q1 2018.
  • Versant Venture Management's portfolio value rose 229% quarter-over-quarter to $313M.

Based on Versant Venture Management's 13F filing for Q1 2018, filed 3 May 2018.